Myology research highlights

RSS feed

DMD and rhabdomyosarcoma share similarities

Canadian researchers have written a book chapter summing up the knowledge acquired in the field of muscle stem cells (also known as satellite cells): these cells, located at the periphery of the muscle fibre, are the basis of muscle regeneration, they have been studied here in the two very different contexts of Duchenne muscular dystrophy … [Read more]

A remote study of the validity of the North Star functional scale

The COVID-19 pandemic provided an opportunity to rethink the methods used to assess functional scores in neuromuscular patients, particularly those with Duchenne muscular dystrophy (DMD): American researchers studied the validity of remote administration of the NSAA (North Star Ambulatory Assessment) scale in the form of a streaming video under the supervision of a physiotherapist, the … [Read more]

Omega3s appear to improve the FOXP3 regeneration biomarker in DMD

Supplementation with long-chain omega-3 polyunsaturated fatty acids (ω-3 LCPUFA) was tested in a double-blind, placebo-controlled study for six months in 31 boys with Duchenne muscular dystrophy (DMD): eighteen were treated with ω-3 LCPUFA and 13 with placebo; leukocyte mRNA levels of the muscle regeneration marker FOXP3 in ambulant participants were higher than in non-ambulant participants; … [Read more]

Myasthenia gravis: mycophenolate and methotrexate better tolerated than azathioprine

A UK national survey of 235 people with myasthenia gravis, 166 on azathioprine, 102 on mycophenolate and 40 on methotrexate, showed that : the most frequent adverse events were liver damage with azathioprine (23%), diarrhoea with mycophenolate (14%) and fatigue with methotrexate (18%); discontinuation of azathioprine due to adverse events was significantly more frequent than … [Read more]

An early marker of myocardial damage in DMD

Catalan clinicians have studied the possibility of early detection of myocardial alterations in Duchenne muscular dystrophy (DMD): 23 adolescents with dystrophinopathy (14 DMD, 8 Becker, 1 symptomatic transmitter) were assessed using cardiac magnetic resonance imaging (cardio-MRI) and cardiac functional parameters, their data were compared with a control group of 173 healthy individuals, the analysis was … [Read more]

ENMC workshop rethinks diagnosis and clinical trial design in inclusion myositis

Ten years after the publication of the diagnostic criteria for inclusion myositis, an international group of around thirty experts (including two from France) took part in the 272nd workshop of the European Neuromuscular Centre (ENMC) in June 2023 in the Netherlands. Their work resulted in: the inclusion of new diagnostic criteria, such as the finding … [Read more]

Expert consensus on the assessment and management of adverse reactions to delandistrogene moxeparvovec (Elevidys®)

Given the rapid and recent development of microdystrophin gene therapy treatments for Duchenne muscular dystrophy (DMD), there is little data on the side effects of these treatments. The Delphi method was used to develop a consensus on the assessment and management of side effects (vomiting, gastritis, acute liver damage, myocarditis, autoimmune myositis) of delandistrogene moxeparvovecavant … [Read more]

An update on good practice in molecular biology for FSHD

Despite substantial advances in its pathophysiology, muscular dystrophy or facioscapulohumeral myopathy (FSHD) remains a complex muscular disease with at least two genes involved. An international consortium has revised the 2012 recommendations on genetic diagnosis:

  • the European consortium dedicated to clinical trials in FSH took the lead on this revision following an ENMC workshop devoted to this subject in 2022,
  • experts from the United States, India, Japan, Australia, South Africa and Brazil were added,
  • the entire consortium took part in six sessions to exchange ideas and compare practices, taking into account new technologies such as molecular combing and opto-genomic mapping,
  • diagnostic procedures were standardised for both FSHD1 and FSHD2, including prenatal diagnosis.

This revision was all the more necessary and useful given the growing number of clinical trials in the field of FSHD.

 

Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines. Giardina E, Camaño P, Burton-Jones S. et al. Clin Genet. 2024 Jul;106(1):13-26. doi: 10.1111/cge.14533. Epub 2024 Apr 29.

Results of losmapimod and antioxidants in FSHD

New trial results have recently been published for facioscapulohumeral muscular dystrophy (FHSD). For losmapimod, they show that :

  • in a phase II trial involving 80 people with FSHD1 aged between 18 and 65, the product slowed the progression of the disease compared with placebo,
  • MRI images showed a slowdown in the replacement of muscle cells by fatty tissue in certain muscles,
  • patients reported significant clinical improvements with losmapimod (PROM),
  • no significant difference was observed in muscle expression of DUX4-regulated genes in losmapimod or placebo (primary endpoint of the trial).

With antioxidants, the results of a trial conducted at Montpellier University Hospital (NCT01596803) showed an improvement in muscle volume and quality, muscle strength and antioxidant response in 10 patients compared with 10 others who received a placebo.

 

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Tawil R, Wagner KR, Hamel JI, et al. Lancet Neurol. 2024 Mai.

 

Muscle strength, quantity and quality and muscle fat quantity and their association with oxidative stress in patients with facioscapulohumeral muscular dystrophy: Effect of antioxidant supplementation. Wilson VD, Bommart S, Passerieux E et al. Free Radic Biol Med. 2024 Juil.

Myasthenia gravis in France seen through the national health data system prism

In order to assess the incidence and prevalence of myasthenia gravis in France, a group of researchers from Auvergne analyzed data contained in the national health data system (SNDS) : the study covered the period 2008-2018, 331 patients were identified in the SNDS, enabling us to extrapolate an incidence of 50 per million inhabitants per … [Read more]